The Senate Judiciary Committee has approved S. 369, the Preserve Access to Affordable Generics Act, which generally would prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market. As approved by the Committee, the bill would allow certain settlement agreements between drug companies if they enhance competition, and it would establish penalties for violations of the act.
Register Now As you are not an existing subscriber please register for your free daily legal newsfeed service.Register
If you have any questions about the service please contact firstname.lastname@example.org or call Lexology Customer Services on +44 20 7234 0606.
Generic drug competition
If you are interested in submitting an article to Lexology, please contact Andrew Teague at email@example.com.
Group Manager, Legal and Business Services
Australian Grand Prix Corporation